Key Highlights

● ZEVASKYN net revenue was $11.4 million, up 31% from the first quarter.

● Five patients were treated in the quarter, with revenue recognised for four.

● Cash and short-term investments totalled $146.8 million at June 30, 2026.

● ZEVASKYN gained new technology add-on payment status from October 1, 2026.

Abeona Therapeutics Inc. (NASDAQ:ABEO), whose common stock trades on the Nasdaq under the ticker ABEO, reported second-quarter 2026 results on 13 August 2026. Net revenue from ZEVASKYN, its autologous cell-based gene therapy for wounds in people with recessive dystrophic epidermolysis bullosa, a severe inherited skin-blistering condition, was $11.4 million. That was 31 per cent higher than the $8.7 million recorded in the first quarter of 2026.

Five patients were treated during the quarter, but revenue was recognised for four of them. Since launch, 12 treatments have been completed, and revenue has not been recognised for two of those patients. Three further treatments had been completed in the third quarter by the date of the release. Because each treatment is a discrete, high-value procedure, quarterly revenue can move sharply with a handful of cases.

Costs, Losses and Cash

The net loss for the quarter was $20.2 million, or $0.35 per share, compared with $17.1 million, or $0.30 per share, in the first quarter. For the six months to 30 June 2026 the loss was $37.3 million. Research and development expense fell to $5.0 million from $9.6 million, because the first quarter had included a one-off $7.0 million upfront cost for in-licensing a PSMA-directed cell therapy candidate, ABO-701. Selling, general and administrative expense declined to $15.8 million from $19.5 million, and cost of sales was about $4.2 million.

Cash, cash equivalents and short-term investments totalled $146.8 million at 30 June 2026, against $191.4 million at the end of 2025, a decline of $44.6 million in six months. The company had 57,225,919 shares of common stock outstanding. The release did not state how long that cash would last.

Treatment Centres and Reimbursement

ZEVASKYN is delivered through qualified treatment centres, and the network now covers seven sites. NewYork-Presbyterian/Columbia and the Children's Hospital of Philadelphia were activated during the second quarter, and the latter has treated its first patient. Cincinnati Children's was announced as a further centre in the third quarter. Expansion matters because patient throughput depends on how quickly centres move from activation to biopsy collection and treatment.

A reimbursement change took effect on 1 October 2026. Under the fiscal 2027 inpatient prospective payment system final rule from the Centers for Medicare & Medicaid Services, ZEVASKYN gained new technology add-on payment status. The company noted that Medicare patients are roughly 10 per cent of the people with this condition, so the direct effect may be modest.

Pipeline and Wider Context

Beyond the approved product, Abeona refers to ABO-701, an engineered T-cell therapy aimed at PSMA, and to a possible future investigational new drug submission. No timetable was given, and the programme is far earlier than the commercial product. The company therefore remains, for now, largely a one-product business, which concentrates both its commercial opportunity and its risk.

A One-Product Launch Gains Traction, With Concentration Risk Attached

The quarter shows a rare-disease launch gradually gaining traction, with higher revenue, lower operating spending and wider centre coverage. Even so, the company is still loss-making, relies on a small number of treatments each quarter and has not disclosed profitability targets. Revenue recognition timing, manufacturing capacity, payer decisions and patient referrals could all alter the trajectory.

The next scheduled disclosure is expected to be the third-quarter 2026 report.